Effect of SGLT2 inhibitors on fractures, bone mineral density (BMD), and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Pooled result · Fracture riskResult — go to the resultPooled relative risk 1.21 95% CI 0.95–1.54Authors' conclusion
The findings suggest that the utilization of SGLT2 inhibitors is not significantly linked to an elevated risk of fractures in individuals with T2DM.
Study context
- Population
- Patients with T2DM
- Participants
- 12,764 patients20 randomised controlled trials (RCTs)
- Comparison
- SGLT2 inhibitors vs control
- Outcome
- Fracture risk
Pooled result
As reported in the abstract
Pooled relative risk
1.21
95% CI 0.95–1.54
SGLT2 inhibitorsvs control
pooled RR 1.21 (95% CI 0.95–1.54)
Further pooled results
BMD change
| WMD (95% CI) | ||
|---|---|---|
| SGLT2 inhibitorsLumbar spine | −0.02 (−0.38 to 0.34) | |
| SGLT2 inhibitorsFemoral neck | 0.11 (−0.28 to 0.50) | |
| SGLT2 inhibitorsTotal hip | −0.20 (−0.41 to 0.01) | |
| SGLT2 inhibitorsDistal forearm | −0.20 (−0.62 to 0.22) | |
| −1−0.500.51Difference (linear scale) |
Bone metabolism markers
| WMD (95% CI) | ||
|---|---|---|
| SGLT2 inhibitorsCTX | 0.04 (−0.02 to 0.09) | |
| SGLT2 inhibitorsP1NP | 1.06 (−0.44 to 2.57) | |
| SGLT2 inhibitorsPTH | 0.34 (−0.07 to 0.75) | |
| SGLT2 inhibitorsCalcium | 0.01 (−0.02 to 0.04) | |
| SGLT2 inhibitorsPhosphate | 2.37 (−0.76 to 5.49) | |
| −50510Difference (linear scale) |
Original publication
Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos Int. Published 11 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →